Next Article in Journal
Thyroid Hormone Effect on the Differentiation of Human Induced Pluripotent Stem Cells into Hepatocyte-Like Cells
Next Article in Special Issue
Phytoestrogens for the Management of Endometriosis: Findings and Issues
Previous Article in Journal
Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 MPro Inhibitor
Previous Article in Special Issue
Myo-Inositol as a Key Supporter of Fertility and Physiological Gestation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

PPARγ Agonists: Emergent Therapy in Endometriosis

by
Alexandre Vallée
1,*,
Jean-Noël Vallée
2,3,
Alain Le Blanche
4,5 and
Yves Lecarpentier
6
1
Department of Clinical Research and Innovation (DRCI), Foch Hospital, 92150 Suresnes, France
2
Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80000 Amiens, France
3
DACTIM-Mis, Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86000 Poitiers, France
4
Laboratoire CeRSM (EA-2931), UPL, Université Paris Nanterre, F92000 Nanterre, France
5
Hôpital René-Dubos de Pontoise and Université de Versailles-Saint-Quentin, Simone Veil UFR des Sciences de la Santé, 78180 Montigny-le-Bretonneux, France
6
Centre de Recherche Clinique, Grand Hôpital de l’Est Francilien (GHEF), 77100 Meaux, France
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(6), 543; https://doi.org/10.3390/ph14060543
Submission received: 10 May 2021 / Revised: 31 May 2021 / Accepted: 4 June 2021 / Published: 6 June 2021
(This article belongs to the Special Issue Novel Regulators of Female Reproduction)

Abstract

Endometriosis is one of the major gynecological diseases of reproductive-age women. This disease is characterized by the presence of glands and stroma outside the uterine cavity. Several studies have shown the major role of inflammation, angiogenesis, adhesion and invasion, and apoptosis in endometriotic lesions. Nevertheless, the mechanisms underlying endometriotic mechanisms still remain unclear and therapies are not currently efficient. The introduction of new agents can be effective by improving the condition of patients. PPARγ ligands can directly modulate these pathways in endometriosis. However, data in humans remain low. Thus, the purpose of this review is to summarize the potential actions of PPARγ agonists in endometriosis by acting on inflammation, angiogenesis, invasion, adhesion, and apoptosis.
Keywords: endometriosis; PPARγ agonists; inflammation; angiogenesis; apoptosis; invasion; adhesion endometriosis; PPARγ agonists; inflammation; angiogenesis; apoptosis; invasion; adhesion

Share and Cite

MDPI and ACS Style

Vallée, A.; Vallée, J.-N.; Le Blanche, A.; Lecarpentier, Y. PPARγ Agonists: Emergent Therapy in Endometriosis. Pharmaceuticals 2021, 14, 543. https://doi.org/10.3390/ph14060543

AMA Style

Vallée A, Vallée J-N, Le Blanche A, Lecarpentier Y. PPARγ Agonists: Emergent Therapy in Endometriosis. Pharmaceuticals. 2021; 14(6):543. https://doi.org/10.3390/ph14060543

Chicago/Turabian Style

Vallée, Alexandre, Jean-Noël Vallée, Alain Le Blanche, and Yves Lecarpentier. 2021. "PPARγ Agonists: Emergent Therapy in Endometriosis" Pharmaceuticals 14, no. 6: 543. https://doi.org/10.3390/ph14060543

APA Style

Vallée, A., Vallée, J.-N., Le Blanche, A., & Lecarpentier, Y. (2021). PPARγ Agonists: Emergent Therapy in Endometriosis. Pharmaceuticals, 14(6), 543. https://doi.org/10.3390/ph14060543

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop